Silver Book Fact

Effectiveness of pneumonia vaccine

PPSV23 (pneumococcal polysaccharide vaccine) protects against 23 types of pneumococcal bacteria and is 60% to 80% effective in preventing pneumococcal bacteremia in adults over the age of 65 who are not immunocompromised.

Ask the Experts: Pneumococcal vaccines. www.immunize.org/askexperts/experts_pneumococcal_vaccines.asp. Published November 1, 2012

Reference

Title
Ask the Experts: Pneumococcal vaccines
Publication Date
Published November 1, 2012
Authors
Immunization Action Coalition
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Potential value of pneumonia vaccine
    Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
  • Eradication of smallpox has saved 40 million lives worldwide
    Since global vaccination efforts wiped out smallpox disease in 1979, infections in 350 million people have been prevented and 40 million lives have been saved.  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.